MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.

ABSTRACT:

Objective

Tau hyperphosphorylation at threonine 217 (pT217) in cerebrospinal fluid (CSF) has recently been linked to early amyloidosis and could serve as a highly sensitive biomarker for Alzheimer's disease (AD). However, it remains unclear whether other tauopathies induce pT217 modifications. To determine if pT217 modification is specific to AD, CSF pT217 was measured in AD and other tauopathies.

Methods

Using immunoprecipitation and mass spectrometry methods, we compared CSF T217 phosphorylation occupancy (pT217/T217) and amyloid-beta (Aβ) 42/40 ratio in cognitively normal individuals and those with symptomatic AD, progressive supranuclear palsy, corticobasal syndrome, and sporadic and familial frontotemporal dementia.

Results

Individuals with AD had high CSF pT217/

SUBMITTER: Sato C 

PROVIDER: S-EPMC8419397 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature